Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

662 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC. Richardson PG, et al. Among authors: san miguel jf. Br J Haematol. 2007 Jun;137(5):429-35. doi: 10.1111/j.1365-2141.2007.06585.x. Epub 2007 Apr 19. Br J Haematol. 2007. PMID: 17451408 Free article. Clinical Trial.
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC. Lee SJ, et al. Among authors: san miguel jf. Br J Haematol. 2008 Nov;143(4):511-9. doi: 10.1111/j.1365-2141.2008.07378.x. Br J Haematol. 2008. PMID: 18986387 Free article. Clinical Trial.
Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.
Mateos MV, Hernández JM, Hernández MT, Gutiérrez NC, Palomera L, Fuertes M, Díaz-Mediavilla J, Lahuerta JJ, de la Rubia J, Terol MJ, Sureda A, Bargay J, Ribas P, de Arriba F, Alegre A, Oriol A, Carrera D, García-Laraña J, García-Sanz R, Bladé J, Prósper F, Mateo G, Esseltine DL, van de Velde H, San Miguel JF. Mateos MV, et al. Among authors: san miguel jf. Blood. 2006 Oct 1;108(7):2165-72. doi: 10.1182/blood-2006-04-019778. Epub 2006 Jun 13. Blood. 2006. PMID: 16772605 Free article. Clinical Trial.
Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, San Miguel JF. Mateos MV, et al. Among authors: san miguel jf. N Engl J Med. 2013 Aug 1;369(5):438-47. doi: 10.1056/NEJMoa1300439. N Engl J Med. 2013. PMID: 23902483 Free article. Clinical Trial.
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.
Mateos MV, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste MA, Sarrá J, Ocio E, Ramírez G, Martínez R, Palomera L, Payer A, Iglesias R, de la Rubia J, Alegre A, Chinea AI, Bladé J, Lahuerta JJ, San Miguel JF. Mateos MV, et al. Among authors: san miguel jf. Haematologica. 2015 Aug;100(8):1096-102. doi: 10.3324/haematol.2015.124818. Epub 2015 Apr 24. Haematologica. 2015. PMID: 25911554 Free PMC article. Clinical Trial.
Treatment for high-risk smoldering myeloma.
Mateos MV, San Miguel JF. Mateos MV, et al. Among authors: san miguel jf. N Engl J Med. 2013 Oct 31;369(18):1764-5. doi: 10.1056/NEJMc1310911. N Engl J Med. 2013. PMID: 24171526 No abstract available.
Smoldering multiple myeloma: when to observe and when to treat?
Mateos MV, San Miguel JF. Mateos MV, et al. Among authors: san miguel jf. Am Soc Clin Oncol Educ Book. 2015:e484-92. doi: 10.14694/EdBook_AM.2015.35.e484. Am Soc Clin Oncol Educ Book. 2015. PMID: 25993213 Free article. Review.
Targeting CD38 by isatuximab and a CD38/CD3xCD28 trispecific T-cell engager in old patients with acute myeloid leukemia.
Martin-Sanchez E, Blanco Fernández L, Kim PS, Bisht K, Wang H, Van de Velde H, Jelinek T, Simoes C, Prosper F, San-Miguel JF, Alfonso A, Bergua Burgues JM, Rodríguez-Veiga R, Vives S, Martínez-Cuadrón D, Montesinos P, Paiva B, Zabaleta A. Martin-Sanchez E, et al. Among authors: san miguel jf. Blood Adv. 2024 May 30:bloodadvances.2024013212. doi: 10.1182/bloodadvances.2024013212. Online ahead of print. Blood Adv. 2024. PMID: 38815228 No abstract available.
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.
Medina-Herrera A, Vazquez I, Cuenca I, Rosa-Rosa JM, Ariceta B, Jimenez C, Fernandez-Mercado M, Larrayoz MJ, Gutierrez NC, Fernandez-Guijarro M, Gonzalez-Calle V, Rodriguez-Otero P, Oriol A, Rosiñol L, Alegre A, Escalante F, De La Rubia J, Teruel AI, De Arriba F, Hernandez MT, Lopez-Jimenez J, Ocio EM, Puig N, Paiva B, Lahuerta JJ, Bladé J, San Miguel JF, Mateos MV, Martinez-Lopez J, Calasanz MJ, Garcia-Sanz R; GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group. Medina-Herrera A, et al. Among authors: san miguel jf. Blood Cancer J. 2024 Apr 29;14(1):74. doi: 10.1038/s41408-024-01053-3. Blood Cancer J. 2024. PMID: 38684670 Free PMC article. Clinical Trial.
662 results